Cervical cancer is one of the most common cancers in women worldwide. Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus or HPV. The virus spreads through sexual contact. It is a malignant tumor of the lower most part of the uterus (womb) that can be prevented by PAP smear screening and a HPV vaccine. A woman with a persistent HPV infection is at greater risk of developing cervical cell abnormalities and cancer than a woman whose infection resolves on its own.
The global cervical cancer diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global cervical cancer diagnostics market segmentation is based on type of test (pap smear tests, colposcopy, HPV testing, endocervical curettage, cone biopsy and loop electrosurgical excision procedure).
The global cervical cancer diagnostics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global cervical cancer diagnostics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global cervical cancer diagnostics market and included in this report are Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp.